San Antonio Breast Cancer Symposium Dec 8, 2022 Circulating Tumor Cell-Guided Treatment Improves Outcomes for Some Breast Cancer Patients Premium Dec 8, 2022 Adding Ibrance to Fulvestrant Doesn't Benefit CDK4/6 Inhibitor-Refractory Breast Cancer Patients Premium Dec 8, 2022 New HER2-Low Category Spurring Efforts to Understand Breast Cancer Biology, Develop Better Tests Premium Dec 7, 2022 SABCS Data Solidifies Enhertu as Preferred Second-, Third-Line HER2-Positive Breast Cancer Treatment Premium Dec 7, 2022 Enhertu Shows Activity in Early-Stage HER2-Low Breast Cancer Patients in Study Reported at SABCS Dec 7, 2022 Kisqali Outperforms Combination Chemo in Aggressive HR-Positive, HER2-Negative Breast Cancer Premium Dec 7, 2022 SABCS Studies Suggest Differences in Breast Cancer Biology Between Black, White Patients Premium Dec 21, 2021 Biocept to Refocus CNSide Assay Plans After FDA Feedback Suggests Targeting Narrower Indications Premium Dec 10, 2021 SABCS Studies Show Promise of ctDNA Analysis in Individualizing CDK4/6 Inhibitor, Endocrine Therapy Premium Dec 10, 2021 Researchers ID Genomic Signature to Risk Stratify Patients With Precancerous Breast Lesions Dec 10, 2021 Real-World Data Points to Racial Disparity in BRCA1/2 Testing Among TNBC Patients Dec 9, 2021 SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance Dec 9, 2021 RxPONDER Update Yields No Clear Guidance on Chemo Decisions for Younger Breast Cancer Patients Premium Dec 8, 2021 AstraZeneca, Daiichi Sankyo Unveil First Datopotamab Deruxtecan TNBC Data at SABCS Dec 8, 2021 PD-L1 Cutoff for TNBC Keytruda Benefit Confirmed in KEYNOTE Analyses, But Questions Linger Dec 7, 2021 ESR1 Mutation Testing May be Informative for Personalizing SERD Treatment, SABCS Studies Show Premium Dec 7, 2021 SABCS Study Highlights Importance of Ranking Biomarker Evidence in Genomic Test Reports Dec 22, 2020 Agendia FLEX Registry Powers Genomics Research on Underrepresented Breast Cancer Patients Premium Dec 15, 2020 Roche's Ipatasertib Shows No PFS Benefit in Phase III, Biomarker-Guided TNBC Trial Premium Dec 11, 2020 Gilead's Trodelvy Benefits TNBC Patients Regardless of Trop-2 Expression, BRCA1/2 Status Premium Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
